Biophysics and Nuclear Medicine
Department of Biophysics and Nuclear Medicine at UM1 and the Montpellier University Hospital

Articles by Emmanuel Deshayes

Vectorized Internal Radiation Therapy (Clinical Studies)
  • Walter, T., Jann, H., Ansquer, C., Deshayes, E., Garcia-Carbonero, R., Teule, A., Baum, R. P., Verberne, H. J., Cwikla, J. B., Srirajaskanthan, R., de Mestier, L., Grana, C. M., Buck, A., Horsch, D., Pavel, M., Dierickx, L. O., Michael, M., Strosberg, J., Kollar, A.,…Team, C. I. (2026). [(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumors (COMPETE): a phase 3, multicenter, randomized, open-label, superiority trial. Lancet. https://doi.org/10.1016/S0140-6736(26)00604-5
  • Giraudet, A. L., Kryza, D., Vija, L., Bailly, C., Deshayes, E., Cachin, F., Salaun, P. Y., & Courbon, F. (2026). Radioligand Therapy (RLT) in France. Eur Urol Focus. https://doi.org/10.1016/j.euf.2026.05.013
  • Baudin, E., Durand, A., Beron, A., Smith, D., Déandreis, D., Taieb, D., Ansquer, C., Dierickx, L., Deshayes, E., Hentic, O., Moalla, S., Menu, Y., Lebtahi, R., Assenat, E., Touchefeu, Y., Guimbaud, R., Dahan, L., Lamartina, L., Cheurfa, N.,…Foulon, S. (2026). [(177)Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumors of the pancreas (OCLURANDOM): a randomized, controlled, phase 2 trial. Lancet Oncol, 27(6), 699–710. https://doi.org/10.1016/s1470-2045(26)00108-7
  • Ilonca, A. D., Gudin-de-Vallerin, A., Guillemard, S., Eberle, M. C., Briant, J., Guiu, S., Deshayes, E., & Fersing, C. (2025). Gastric Metastases From Invasive Lobular Breast Carcinoma, Identified by [18F]FDG PET/CT, 20 Years After Primary Diagnosis: A Case Report. Clinical Case Reports, 13(9), e70881. https://doi.org/10.1002/ccr3.70881
  • Tran-Gia, J., Cicone, F., Koole, M., Giammarile, F., Gear, J., Deshayes, E., Gabina, P. M., Cremonesi, M., Wadsley, J., Bernhardt, P., Bardies, M., Gnesin, S., Sandstrom, M., Garske-Roman, U., Revheim, M. R., Verburg, F. A., Konijnenberg, M., Krause, B. J., Lassmann, M., & Stokke, C. (2025). Rethinking Dosimetry: A European Perspective. J Nucl Med, 66(9), jnumed.124.269378. https://doi.org/10.2967/jnumed.124.269378
  • Capdevila, J., Pubul, V., Anido, U., Walter, T., Molina-Cerrillo, J., Alonso-Gordoa, T., Garcia-Carbonero, R., San-Roman-Gil, M., Llana, B., Jimenez-Fonseca, P., Benavent Vinuales, M., Ansquer, C., Baudin, E., Lepage, C., Del Olmo-Garcia, M., Ruffinelli, J. C., Beron, A., Haissaguerre, M., Deshayes, E.,…Durand, A. (2025). A randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer, 25(1), 613. https://doi.org/10.1186/s12885-025-13941-3
  • Deshayes, E., Karfis, I., Santoro, L., Mileva, M., Danieli, R., Hebert, K., Maccauro, M., Chiesa, C., & Bardies, M. (2025). Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward! J Nucl Med, 66(6), 983. https://doi.org/10.2967/jnumed.124.268880
  • Hebert, K., Bodin-Cufi, P., Fersing, C., & Deshayes, E. (2024). New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer. Eur Urol Focus, 10(4), 514–517. https://doi.org/10.1016/j.euf.2024.07.016
  • Hebert, K., Santoro, L., Monnier, M., Castan, F., Berkane, I., Assenat, E., Fersing, C., Gelibert, P., Pouget, J. P., Bardies, M., Kotzki, P. O., & Deshayes, E. (2024). Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [(177)Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. J Nucl Med, 65(6), 923–930. https://doi.org/10.2967/jnumed.123.267023
  • Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023). 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinical Practice. Pharmaceutics, 15(4), 1051. https://doi:10.3390/pharmaceutics15041051
  • Barakat, A., Santoro, L., Vivien, M., Kotzki, P. O., Deshayes, E., & Khier, S. (2023). Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera((R))) Case. European Journal of Drug Metabolism and Pharmacokinetics, 48(4), 329–339. https://doi.org/10.1007/s13318-023-00829-5
  • Deshayes, E., Fersing, C., Thibault, C., Roumiguie, M., Pourquier, P., & Houede, N. (2023a). Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: A Radiochemical Perspective and Recent Therapeutic Practices. Cancers (Basel), 15(12), 3133. https://doi.org/10.3390/cancers15123133
  • Deshayes, E., Assenat, E., Meignant, L., Bardies, M., Santoro, L., & Gourgou, S. (2022). A prospective, randomized, phase II study to assess retreatment regimens with Lutathera® in patients with newly progressive intestinal, well-differentiated neuroendocrine tumors (ReLUTH). BMC Cancer, 22(1), 1346. https://doi.org/10.1186/s12885-022-10443-4
  • Allimant, C., Deshayes, E., Kafrouni, M., Santoro, L., de Verbizier, D., Fourcade, M., Cassinotto, C., Hermida, M., Guillot, C., Mariano-Goulart, D., & Guiu, B. (2021). Hepatobiliary Scintigraphy and Glass (90)Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Untreated Liver. Diagnostics (Basel), 11(6), 931. https://doi.org/10.3390/diagnostics11060931
  • Deshayes, E., Roumiguie, M., Thibault, C., Beuzeboc, P., Cachin, F., Hennequin, C., Huglo, D., Rozet, F., Kassab-Chahmi, D., Rebillard, X., & Houede, N. (2017). Radium-223 dichloride for prostate cancer treatment. Drug Design, Development, and Therapy, 11, 2643–2651. https://doi.org/10.2147/DDDT.S122417
  • Deshayes, E., Kraeber-Bodere, F., Vuillez, J. P., Bardies, M., Teulon, I., & Pouget, J. P. (2013). Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in patients with refractory or relapsed non-Hodgkin lymphoma. Immunotherapy, 5(12), 1283–1286. https://doi.org/10.2217/imt.13.138
Methodology: Dosimetry and Radiopharmacy
  • Perrin, O., Benkhoris, S., Vanney, J., Barthelemi, L., Boudousq, V., Deshayes, E., Guisset, C., Soulairol, I., Rubira, L., Fersing, C., & Alize, D. (2026). Expanding (68)Ga radiolabeling capacity: off-label use of PSMA-11 single-vial cold kits through aliquoting and dual generator utilization. In EJNMMI Radiopharm Chem. https://doi.org/10.1186/s41181-026-00459-7
  • Fragoso-Negrin, J. A., Vergara-Gil, A., Rahman Hakim, A., Hardiansyah, D., Glatting, G., Ferrer, L., Varmenot, N., Santoro, L., Veloza-Awad, S., Hebert, K., Deshayes, E., & Bardies, M. (2025). OpenDose3D: A Free, Open-Source Clinical Dosimetry Software for Patient-Specific Dosimetry. J Nucl Med. https://doi.org/10.2967/jnumed.125.269539
  • Fragoso-Negrin, J. A., Santoro, L., Hebert, K., Kafrouni, M., Vauclin, S., Kotzki, P. O., Pouget, J. P., Deshayes, E., & Bardies, M. (2025). Methodology for comparing absorbed dose rate calculation algorithms in molecular radiotherapy dosimetry. Phys Med, 133, 104965. https://doi.org/10.1016/j.ejmp.2025.104965
  • Donze, C., Rubira, L., Santoro, L., Viarasakd, M., Kotzki, P. O., Deshayes, E., & Fersing, C. (2024). (177) Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods. Eur J Hosp Pharm, 31(3), 207–211. https://doi.org/10.1136/ejhpharm-2022-003489
  • Souche, C., Fouillet, J., Rubira, L., Donzé, C., Deshayes, E., & Fersing, C. (2024). Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy. International Journal of Molecular Sciences, 25(1), 462.
  • Souche, C., Fouillet, J., Rubira, L., Donze, C., Salle, A., Dromard, Y., Deshayes, E., & Fersing, C. (2024). Toward Optimal Automated (68)Ga-Radiolabeling Conditions for the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate. J Labelled Comp Radiopharm, 67(14), 441–453. https://doi.org/10.1002/jlcr.4128
  • Rubira, L., Donze, C., Fouillet, J., Algudo, B., Kotzki, P. O., Deshayes, E., & Fersing, C. (2024). [(68)Ga]Ga-FAPI-46 synthesis on a GAIA(R) module system: A thorough study of the automated radiolabeling reaction conditions. Appl Radiat Isot, 206, 111211. https://doi.org/10.1016/j.apradiso.2024.111211
  • Fouillet, J., Donze, C., Deshayes, E., Santoro, L., Rubira, L., & Fersing, C. (2024). “One Method to Label Them All”: A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Adaptable to PSMA-I&T and PSMA-617. Curr Radiopharm, 17(3), 285–301. https://doi.org/10.2174/0118744710293461240219111852
  • Donze, C., Rubira, L., Kotzki, P. O., Deshayes, E., & Fersing, C. (2022). Tailored Media-Fill Test Protocols Inspired by (68)Ga Kit-Based Radiopharmaceuticals. PDA J Pharm Sci Technol, 76(5), 416–433. https://doi.org/10.5731/pdajpst.2021.012657
  • Fersing, C., Masurier, N., Rubira, L., Deshayes, E., & Lisowski, V. (2022). AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. Pharmaceuticals (Basel), 15(2), 234. https://doi.org/10.3390/ph15020234
  • Donze, C., Rubira, L., Santoro, L., Kotzki, P. O., Deshayes, E., & Fersing, C. (2022). Development and Implementation of a Professional Practices Evaluation during Radiopharmaceutical Administration. Healthcare (Basel), 10(11), 2247. https://doi.org/10.3390/healthcare10112247
  • Fersing, C., Deshayes, E., Langlet, S., Calas, L., Lisowski, V., & Kotzki, P. O. (2021). Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators. EJNMMI Radiopharm Chem, 6(1), 2. https://doi.org/10.1186/s41181-020-00117-6
  • Santoro, L., Pitalot, L., Trauchessec, D., Mora-Ramirez, E., Kotzki, P. O., Bardies, M., & Deshayes, E. (2021). Clinical implementation of PLANET® Dose for dosimetric assessment after [(177)Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res, 11(1), 1. https://doi.org/10.1186/s13550-020-00737-8
  • Deshayes, E., Fersing, C., Hebert, K., Bardies, M., Kotzki, P. O., & Santoro, L. (2021). Whole-body planar and 3D quantitative imaging after (177)Lu-DOTATATE on a CZT SPECT/CT device with a MEHRS collimator. First report. Hell J Nucl Med, 24(2), 165–166. https://doi.org/10.1967/s002449912361
  • Mora-Ramirez, E., Santoro, L., Cassol, E., Ocampo-Ramos, J. C., Clayton, N., Kayal, G., Chouaf, S., Trauchessec, D., Pouget, J. P., Kotzki, P. O., Deshayes, E., & Bardies, M. (2020). Comparison of commercial dosimetric software platforms in patients treated with (177)Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys, 47(9), 4602–4615. https://doi.org/10.1002/mp.14375
  • Santoro, L., Mora-Ramirez, E., Trauchessec, D., Chouaf, S., Eustache, P., Pouget, J.-P., Kotzki, P.-O., Bardiès, M., & Deshayes, E. (2018). Implementation of patient dosimetry in clinical practice following targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Research, 8(1), 103. https://doi.org/10.1186/s13550-018-0459-4
Preclinical Research and Radiobiology
  • Constanzo, J., Parach, A., David, T., Karam, J., Bruchertseifer, F., Morgenstern, A., Jarlier, M., Bardies, M., Deshayes, E., Gudin-de-Vallerin, A., Boissiere-Michot, F., Lopez-Crapez, E., & Pouget, J. P. (2025). MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy. J Nucl Med, 66(5), 785–792. https://doi.org/10.2967/jnumed.124.268857
  • Mangeat, T., Mairaville, C., Chentouf, M., Neiveyans, M., Pugnière, M., Ngo, G., Denis, V., Catherine, C., Pichard, A., Deshayes, E., Maurel, M., Gracia, M., Bigot, A., Mouly, V., Estaran, S., Chavanieu, A., Martineau, P., & Robert, B. (2025). Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL. Antibodies, 14(4), 83.
  • Constanzo, J., Bouden, Y., Godry, L., Kotzki, P. O., Deshayes, E., & Pouget, J. P. (2023). Immunomodulatory effects of targeted radionuclide therapy. In International Review of Cell and Molecular Biology. Academic Press. https://doi.org/10.1016/bs.ircmb.2023.02.001
  • Mangeat, T., Gracia, M., Pichard, A., Poty, S., Martineau, P., Robert, B., & Deshayes, E. (2023). Fc-engineered monoclonal antibodies to reduce off-target liver uptake. EJNMMI Res, 13(1), 81. https://doi.org/10.1186/s13550-023-01030-0
  • Pouget, J. P., Santoro, L., Piron, B., Paillas, S., Ladjohounlou, R., Pichard, A., Poty, S., Deshayes, E., Constanzo, J., & Bardies, M. (2022). From the Target Cell Theory to a More Integrated View of Radiobiology in Targeted Radionuclide Therapy: The Montpellier Group’s Experience. Nucl Med Biol, 104–105, 53–64. https://doi.org/10.1016/j.nucmedbio.2021.11.005
  • Ashraf, Y., Mansouri, H., Laurent-Matha, V., Alcaraz, L. B., Roger, P., Guiu, S., Derocq, D., Robin, G., Michaud, H. A., Delpech, H., Jarlier, M., Pugniere, M., Robert, B., Puel, A., Martin, L., Landomiel, F., Bourquard, T., Achour, O., Fruitier-Arnaudin, I.,…Liaudet-Coopman, E. (2019). Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer, 7(1), 29. https://doi.org/10.1186/s40425-019-0498-z
  • Ladjohounlou, R., Lozza, C., Pichard, A., Constanzo, J., Karam, J., Le Fur, P., Deshayes, E., Boudousq, V., Paillas, S., Busson, M., Le Blay, M., Jarlier, M., Marcatili, S., Bardies, M., Bruchertseifer, F., Morgenstern, A., Torgue, J., Navarro-Teulon, I., & Pouget, J. P. (2019). Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clin Cancer Res, 25(15), 4775–4790. https://doi.org/10.1158/1078-0432.CCR-18-3295
  • Deshayes, E., Ladjohounlou, R., Le Fur, P., Pichard, A., Lozza, C., Boudousq, V., Sevestre, S., Jarlier, M., Kashani, R., Koch, J., Sosabowski, J., Foster, J., Chouin, N., Bruchertseifer, F., Morgenstern, A., Kotzki, P. O., Navarro-Teulon, I., & Pouget, J. P. (2018). Radiolabeled Antibodies Against the Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. J Nucl Med, 59(8), 1234–1242. https://doi.org/10.2967/jnumed.118.208611
  • Estupina, P., Fontayne, A., Barret, J. M., Kersual, N., Dubreuil, O., Le Blay, M., Pichard, A., Jarlier, M., Pugniere, M., Chauvin, M., Chardes, T., Pouget, J. P., Deshayes, E., Rossignol, A., Abache, T., de Romeuf, C., Terrier, A., Verhaeghe, L., Gaucher, C.,…Navarro-Teulon, I. (2017). The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget, 8(23), 37061–37079. https://doi.org/10.18632/oncotarget.15715
  • Paillas, S., Ladjohounlou, R., Lozza, C., Pichard, A., Boudousq, V., Jarlier, M., Sevestre, S., Le Blay, M., Deshayes, E., Sosabowski, J., Chardes, T., Navarro-Teulon, I., Mairs, R. J., & Pouget, J. P. (2016). Localized Irradiation of Cell Membranes by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxid Redox Signal, 25(8), 467–484. https://doi.org/10.1089/ars.2015.6309
  • Pouget, J. P., Lozza, C., Deshayes, E., Boudousq, V., & Navarro-Teulon, I. (2015). Introduction to the radiobiology of targeted radionuclide therapy. Front Med (Lausanne), 2, 12. https://doi.org/10.3389/fmed.2015.00012
  • Buchegger, F., Baechler, S., Bühler, L., Deshayes, E., Gottberg, A., Kosinski, M., Maecke, H. R., Mansi, R., Müller, C., Prior, J. O., Schibli, R., & Stora, T. (2014). 37: 152/161Tb-DOTA-RM6 biodistribution studies in SCID mice with prostate cancer and 149Tb sources from CERN-MEDICIS. Radiotherapy and Oncology, 110, S18–S19. https://doi.org/10.1016/s0167-8140(15)34058-5
Scintigraphic and PET Imaging in Oncology
  • Assenat, E., Blanc, J.-F., Bouattour, M., Gauthier, L., Deshayes, E., Guillemard, S., Touchefeu, Y., Portales, F., Borg, C., Harguem, L., Guimbaud, R., Ychou, M., & Mazard, T. (2025). Regorafenib plus modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. (April 1, 2025). Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf080
  • Chanchou, M., Mouret-Reynier, M. A., Molnar, I., Deshayes, E., D’Hondt, V., Bourahla, K., Petit, T., Bardet, S., Levy, C., Morel, O., Augereau, P., Rousseau, C., Campone, M., Monteil, J., Venat-Bouvet, L., Faye, A., Benavent, V., & Cachin, F. (2025). (18)F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2+ breast cancer patients: a prospective and multicenter French study. Breast Cancer Res. https://doi.org/10.1186/s13058-025-02156-w
  • Combet-Curt, V., Buchalet, C., Malicot, K. L., Lemanski, C., Deshayes, E., Bonichon-Lamichhane, N., Lievre, A., Huguet, F., Tlili, G., & Vendrely, V. (2024). Prognostic Value of (18)F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicenter Cohort FFCD-ANABASE. J Nucl Med, 65(8), 1194–1201. https://doi.org/10.2967/jnumed.124.267626
  • Rouanet, P., Castan, F., Mazard, T., Lemanski, C., Nougaret, S., Deshayes, E., Chalbos, P., Gourgou, S., Taoum, C., & Greccar, P. et al. (2023). GRECCAR 14 – a multicenter, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favorable response to induction chemotherapy: Study protocol. Colorectal Dis, 25(10), 2078–2086. https://doi.org/10.1111/codi.16740
  • Galvez, T., Berkane, I., Thézenas, S., Eberlé, M.-C., Flori, N., Guillemard, S., Ilonca, A. D., Santoro, L., Kotzki, P.-O., Senesse, P., & Deshayes, E. (2023). Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer. Nutrients, 15(13), 3042.
  • Meng, J., Deshayes, E., Zhang, L., Shi, W., Zhang, X., Chen, X., Mei, X., Ma, J., Jiang, Y., Wu, J., Shao, Z., Yu, X., Yang, Z., & Guo, X. (2021). Prognostic value of metabolic signature based on 18F-FDG uptake in breast cancer patients after radiotherapy. Mol Ther Oncolytics, 23, 412–419. https://doi.org/10.1016/j.omto.2021.10.008
  • Deshayes, E., de Forges, H., Fraisse, J., Eberle, M. C., Guillemard, S., Fallieres, A., Pouget, J. P., Tetreau, R., Kotzki, P. O., Santoro, L., Senesse, P., & Flori, N. (2019). Artificial nutrition in patients with cancer has no impact on tumor glucose metabolism: Results of the PETANC Study. Clin Nutr, 38(5), 2121–2126. https://doi.org/10.1016/j.clnu.2018.08.033
  • Riou, O., Llacer Moscardo, C., Fenoglietto, P., Deshayes, E., Tetreau, R., Molinier, J., Lenglet, A., Assenat, E., Ychou, M., Guiu, B., Ailleres, N., Bedos, L., & Azria, D. (2017). SBRT planning for liver metastases: A focus on immobilization, motion management, and planning imaging techniques. Rep Pract Oncol Radiother, 22(2), 103–110. https://doi.org/10.1016/j.rpor.2017.02.006
  • Tetreau, R., Llacer, C., Riou, O., & Deshayes, E. (2017). Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother, 22(2), 170–175. https://doi.org/10.1016/j.rpor.2015.12.004
  • Ricard, F., Cimarelli, S., Deshayes, E., Mognetti, T., Thiesse, P., & Giammarile, F. (2011). Additional Benefits of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric Rhabdomyosarcoma. Clin Nucl Med, 36(8), 672–677. https://doi.org/10.1097/RLU.0b013e318217ae2e
  • Cimarelli, S., Deshayes, E., Mognetti, T., Biron, P., Desuzinges, C., Rivoire, M., & Giammarile, F. (2009). F-18 FDG PET/CT imaging in a case of primary choriocarcinoma in the retroperitoneum. Clin Nucl Med, 34(7), 449–451. https://doi.org/10.1097/RLU.0b013e3181a7d0cd
Scintigraphic and PET imaging OUTSIDE of oncology
  • Dubois, J., Deshayes, E., Kucharczak, F., Cadet, M. M., Zhou, J., Paunet, T., & Fersing, C. (2026). Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective. EJNMMI Radiopharmacy and Chemistry, 11(1). https://doi.org/10.1186/s41181-025-00418-8
  • Guillemard, S., Moulis, L., Ilonca, D., Mestre, S., Deshayes, E., Quéré, I., & Adham, S. (2024). LYMPHOSCORE (Lymphoscintigraphy Scoring Reliability): Reliability of a New Qualitative and Semiquantitative Lymphoscintigraphy Scoring System for Primary Lymphedema. Clin Nucl Med, 49(9), e428–e435. https://doi.org/10.1097/rlu.0000000000005357
  • Bordeau, K., Eberle, M. C., Fabbro, M., Fersing, C., & Deshayes, E. (2022). Lumbosacral Plexus Neurolymphomatosis: A Typical 18FDG PET/CT Pattern to Recognize. Clin Nucl Med, 47(4), 352–353. https://doi.org/10.1097/RLU.0000000000003949
  • Eberle, M. C., Fersing, C., Guillemard, S., Ilonca, D., Guiu, S., & Deshayes, E. (2022). Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean? Diagnostics (Basel), 12(4), 934. https://doi.org/10.3390/diagnostics12040934
  • Nesterov, S. V., Sciagra, R., Orozco, L. E. J., Prior, J. O., Settimo, L., Han, C., Deshayes, E., deKemp, R. A., Ryzhkova, D. V., Gwet, K. L., & Knuuti, J. M. (2022). One-tissue compartment model for myocardial perfusion quantification with N-13 ammonia PET provides matching results: A cross-comparison between Carimas, FlowQuant, and PMOD. J Nucl Cardiol, 29(5), 2543–2550. https://doi.org/10.1007/s12350-021-02741-4
  • Dietz, M., Kamani, C. H., Deshayes, E., Dunet, V., Mitsakis, P., Coukos, G., Nicod Lalonde, M., Schaefer, N., & Prior, J. O. (2021). Imaging angiogenesis in atherosclerosis in large arteries with (68)Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI Res, 11(1), 71. https://doi.org/10.1186/s13550-021-00815-5
  • Nesterov, S. V., Deshayes, E., Juarez-Orozco, L. E., deKemp, R. A., Sciagra, R., Malaspina, S., Settimo, L., Han, C., Ryzhkova, D. V., Kostina, I. S., Gwet, K. L., Prior, J. O., & Knuuti, J. M. (2022). Myocardial perfusion quantification with Rb-82 PET: good interobserver agreement of Carimas software at global, regional, and segmental levels. Ann Nucl Med, 36(6), 507–514. https://doi.org/10.1007/s12149-022-01729-5
  • Gnesin, S., Mitsakis, P., Cicone, F., Deshayes, E., Dunet, V., Gallino, A. F., Kosinski, M., Baechler, S., Buchegger, F., Viertl, D., & Prior, J. O. (2017). First in-human radiation dosimetry of (68)Ga-NODAGA-RGDyK. EJNMMI Res, 7(1), 43. https://doi.org/10.1186/s13550-017-0288-x
  • Nesterov, S. V., Deshayes, E., Sciagra, R., Settimo, L., Declerck, J. M., Pan, X. B., Yoshinaga, K., Katoh, C., Slomka, P. J., Germano, G., Han, C., Aalto, V., Alessio, A. M., Ficaro, E. P., Lee, B. C., Nekolla, S. G., Gwet, K. L., deKemp, R. A., Klein, R.,…Knuuti, J. M. (2014). Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 Study. JACC Cardiovasc Imaging, 7(11), 1119–1127. https://doi.org/10.1016/j.jcmg.2014.08.003
  • Deshayes, E., Le Berre, J. P., Jouanneau, E., Vasiljevic, A., Raverot, G., & Seve, P. (2013). 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med, 38(1), e50–52. https://doi.org/10.1097/RLU.0b013e31825ae73b
  • Duranton, F., Lacoste, A., Faurous, P., Deshayes, E., Ribstein, J., Avignon, A., Mourad, G., & Argiles, A. (2013). Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. Clin Kidney J, 6(5), 478–483. https://doi.org/10.1093/ckj/sft092
  • Rahmi, A., Deshayes, E., Maucort-Boulch, D., Varron, L., Grange, J. D., Kodjikian, L., & Seve, P. (2012). Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labeled fluorodeoxyglucose positron emission tomography. Br J Ophthalmol, 96(1), 99–103. https://doi.org/10.1136/bjo.2010.194514
scintigraphic imaging of liver function
  • Cusumano, C., Deshayes, E., Guiu, B., De Meeus, G., Carrere, S., Bouillin, A., Ilonca, D., Eberle, M. C., Guillemard, S., Fersing, C., Sgarbura, O., & Quenet, F. (2023). Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepatobiliary scintigraphy the optimal tool? Ann Transl Med, 11(5), 202. https://doi.org/10.21037/atm-22-3665
  • Guiu, B., Deshayes, E., Panaro, F., Sanglier, F., Cusumano, C., Herrerro, A., Sgarbura, O., Molinari, N., Quenet, F., & Cassinotto, C. (2021). (99m)Tc-mebrofenin hepatobiliary scintigraphy and volume metrics before liver preparation: correlations and discrepancies in non-cirrhotic patients. Ann Transl Med, 9(9), 795. https://doi.org/10.21037/atm-20-7372
  • Memeo, R., Conticchio, M., Deshayes, E., Nadalin, S., Herrero, A., Guiu, B., & Panaro, F. (2021). Optimization of the future remnant liver: a review of current strategies in Europe. Hepatobiliary Surg Nutr, 10(3), 350–363. https://doi.org/10.21037/hbsn-20-394
  • Piron, L., Deshayes, E., Cassinotto, C., Quenet, F., Panaro, F., Hermida, M., Allimant, C., Assenat, E., Pageaux, G. P., Molinari, N., & Guiu, B. (2020). Deportalization, Venous Congestion, Venous Deprivation: Serial Measurements of Volumes and Functions on Morphofunctional 99mTc-Mebrofenin SPECT-CT. Diagnostics (Basel), 11(1), 12. https://doi.org/10.3390/diagnostics11010012
  • Deshayes, E., Piron, L., Bouvier, A., Lapuyade, B., Lermite, E., Vervueren, L., Laurent, C., Pinaquy, J. B., Chevallier, P., Dohan, A., Rode, A., Sengel, C., Guillot, C., Quenet, F., & Guiu, B. (2020). Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective, and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colorectal liver metastases. BMC Cancer, 20(1), 574. https://doi.org/10.1186/s12885-020-07065-z
  • Guiu, B., Quenet, F., Panaro, F., Piron, L., Cassinotto, C., Herrerro, A., Souche, F. R., Hermida, M., Pierredon-Foulongne, M. A., Belgour, A., Aho-Glele, S., & Deshayes, E. (2020). Liver venous deprivation versus portal vein embolization before major hepatectomy: future volumetric and functional changes in the residual liver. Hepatobiliary Surg Nutr, 9(5), 564–576. https://doi.org/10.21037/hbsn.2020.02.06
  • Deshayes, E., Fersing, C., Meunier, L., Quenet, F., & Guiu, B. (2019). Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to a Dramatic Underestimation of Liver Function with 99mTc-Mebrofenin Hepatobiliary Scintigraphy. Clin Nucl Med, 45(2), 133–135. https://doi.org/10.1097/rlu.0000000000002861
  • Quenet, F., Pissas, M. H., Gil, H., Roca, L., Carrere, S., Sgarbura, O., Rouanet, P., de Forges, H., Khellaf, L., Deshayes, E., Ychou, M., & Bibeau, F. (2019). Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. Surgery, 165(4), 703–711. https://doi.org/10.1016/j.surg.2018.10.006
  • Panaro, F., Giannone, F., Riviere, B., Sgarbura, O., Cusumano, C., Deshayes, E., Navarro, F., Guiu, B., & Quenet, F. (2019). Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center. Hepatobiliary Surgery and Nutrition, 8(4), 329–337. https://doi.org/10.21037/hbsn.2019.07.06
  • Deshayes, E., Schadde, E., Piron, L., Quenet, F., & Guiu, B. (2017). Extended Liver Venous Deprivation Leads to a Greater Increase in Liver Function Than ALPPS in Early Assessment: A comment on “Sparrelid, E. et al. Dynamic Evaluation of Liver Volume and Function in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. Journal of Gastrointestinal Surgery (2017).” J Gastrointest Surg, 21(10), 1754–1755. https://doi.org/10.1007/s11605-017-3508-9
  • Guiu, B., Quenet, F., Escal, L., Bibeau, F., Piron, L., Rouanet, P., Fabre, J. M., Jacquet, E., Denys, A., Kotzki, P. O., Verzilli, D., & Deshayes, E. (2017). Extended liver venous deprivation before major hepatectomy induces a marked and very rapid increase in future liver remnant function. Eur Radiol, 27(8), 3343–3352. https://doi.org/10.1007/s00330-017-4744-9
  • Deshayes, E., & Guiu, B. (2016). Liver function: homogeneous or not? HPB (Oxford), 18(11), 871. https://doi.org/10.1016/j.hpb.2016.07.017
Publications in French
  • Bailly, C., Giraudet, A. L., Turpin, L., Claudin, M., Tonnelet, D., Habouzit, V., Merlin, C., Deshayes, E., Lussey, C., Robin, P., Deandreis, D., Dekyndt, B., Lamesa, C., Dieudonné, A., Badel, J. N., Courbon, F., & Vija, L. (2026). Vectorized internal radiation therapy and theranostics in France: best practice recommendations from the French Society of Nuclear Medicine. Nuclear Medicine. https://doi.org/10.1016/j.mednuc.2026.02.001
  • Courbon, F., Kotzki, P. O., Boudousq, V., Fersing, C., Salaun, P. Y., & Deshayes, E. (2025). Letter to the Editor regarding the article “Therapeutic Innovation and Capacity Challenges in Nuclear Medicine: The Situation of RIV in Occitanie” by Guignard et al. (1). Nuclear Medicine, 49(5), 257–259. https://doi.org/10.1016/j.mednuc.2025.06.008
  • Guillemard, S., Moulis, L., Ilonca, D., Godin, S. M., Deshayes, E., Quere, I., & Adham, S. (2025). LYMPHOSCORE. A new qualitative and semi-quantitative evaluation system for lower extremity lymphoscintigraphy. Vascular Diseases, 50(1), 35. https://doi.org/10.1016/j.vasdi.2025.01.015 (Original work published: LYMPHOSCORE. A new qualitative and semi-quantitative evaluation system for lower extremity lymphoscintigraphy.)
  • Giraudet, A. L., Hamon, P. A., Coulot, J., Pascal, P., Deshayes, E., Courbon, F., & Salaun, P. Y. (2024a). 2023–2024 Theranostic Capacity Study – Modeling Based on VIR-PSMA. Vectorized Internal Radiotherapy (RIV): A Theranostic Approach That Patients Should Have Access To. Part I: National Consolidation. Nuclear Medicine, 48(4-5), 169–188. https://doi.org/10.1016/j.mednuc.2024.09.001
  • Giraudet, A. L., Hamon, P. A., Coulot, J., Pascal, P., Deshayes, E., Courbon, F., & Salaun, P. Y. (2024b). 2023–2024 Theranostic Capacity Study – Modeling Based on VIR-PSMA. Vectorized Internal Radiotherapy (RIV): A Theranostic Approach to Which Patients Must Have Access. Part II: In-Depth Analysis. Nuclear Medicine, 48(4-5), 189–223. https://doi.org/10.1016/j.mednuc.2024.09.002
  • Assenat, E., & Deshayes, E. (2021). Targeted brachytherapy and the treatment of endocrine tumors: history, practical approaches, and future prospects. Hépato-Gastro & Oncologie Digestive, 28(4), 520–531. https://doi.org/10.1684/hpg.2021.2153
  • Chanchou, M., Mouret-Reynier, M. A., Cougoul, A., Deshayes, E., D’Hondt, V., Bourahla, K., Petit, T., Bardet, S., Levy, C., Morel, O., Augereau, P., Rousseau, C., Campone, M., Monteil, J., Venat-Bouvet, L., Benavent, V., & Cachin, F. (2020). Value of 18FDG PET for predicting therapeutic response in HER2+ breast cancer: Interim analysis. Médecine Nucléaire, 44(3), 181–188. https://doi.org/10.1016/j.mednuc.2020.02.003
  • Piron, L., Deshayes, E., Escal, L., Souche, R., Herrero, A., Pierredon-Foulongne, M. A., Assenat, E., le Lam, N., Quenet, F., & Guiu, B. (2017). [Portal vein embolization: Present and future]. Bull Cancer, 104(5), 407–416. https://doi.org/10.1016/j.bulcan.2017.03.009 (Original work published as “Preoperative portal vein embolization: present and future.”)
  • Deshayes, E., Collinot, J. A., Dunet, V., Allenbach, G., Mitsakis, P., Muller, O., & Prior, J. O. (2013). Quantitative analysis in cardiac PET. Nuclear Medicine, 37(5), 181–186. https://doi.org/10.1016/j.mednuc.2013.03.168
  • Collinot, J. A., Deshayes, E., Dunet, V., Iglesias, J. I., Trana, C., Muller, O., & Prior, J. O. (2012). Agreement between coronary angiography and myocardial perfusion reserve measured by rubidium-82 cardiac PET/CT. Nuclear Medicine, 36(4), 163–164. https://doi.org/10.1016/j.mednuc.2012.02.025
  • Deshayes, E., Dunet, V., Rüegg, C., & Prior, J. O. (2012). Imaging of neoangiogenesis in nuclear medicine. Nuclear Medicine, 36(10), 619–626. https://doi.org/10.1016/j.mednuc.2012.07.010
  • Guigal, V., Pialat, J. B., Vilayphiou, N., Deshayes, E., Rizzo, C., & Gazarian, A. (2010). [Bone quality evaluation in allograft hand transplants]. Chir Main, 29 Suppl 1, S199–213. https://doi.org/10.1016/j.main.2010.10.008 (Original work published: Evaluation of bone quality in hand allografts.)
  • Audigier, C., Billotey, C., Deshayes, E., Banayan, S., & Janier, M. (2009). The Role of 18FDG PET in Localizing Primary Tumors. Nuclear Medicine, 33(8), 508–511. https://doi.org/10.1016/j.mednuc.2009.06.011

Links to: